A side-by-side look at tirzepatide and semaglutide — how they work, what clinical trials show, and how they differ for type 2 diabetes management.
| Ozempic | Mounjaro | |
|---|---|---|
| Drug class | GLP-1 receptor agonist | Dual GLP-1 / GIP receptor agonist |
| Active ingredient | semaglutide | tirzepatide |
| Receptor targets | GLP-1 | GLP-1 + GIP |
| FDA-approved indication | Type 2 diabetes; cardiovascular risk reduction | Type 2 diabetes |
| Available strengths | 0.5 mg, 1 mg, 2 mg pens | 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg pens |
| Administration | Subcutaneous injection, once weekly | Subcutaneous injection, once weekly |
| Cardiovascular outcome trial | SUSTAIN-6; SELECT (CV benefit in non-diabetic obese patients) | SURPASS-CVOT (ongoing/reported); head-to-head SURPASS-2 |
| Weight loss version | Wegovy (semaglutide, higher strength) | Zepbound (tirzepatide, same molecule) |
| Oral form available | Rybelsus (oral semaglutide) — separate product | No |
| Manufacturer | Novo Nordisk | Eli Lilly |
| Generic available | No | No |
| Estimated list price | ~$900–1,000/month without insurance | ~$900–1,000/month without insurance |
Semaglutide mimics glucagon-like peptide-1, stimulating insulin release in response to meals, suppressing glucagon, and slowing gastric emptying. The result is improved blood sugar control and reduced appetite.
Tirzepatide is a single molecule that activates both GLP-1 and GIP receptors simultaneously. GIP receptor activation may enhance fat cell metabolism and complement GLP-1 signaling in ways that produce greater average weight reduction.
Demonstrated significant reduction in major adverse cardiovascular events (MACE) in adults with type 2 diabetes and high cardiovascular risk, supporting the expanded FDA indication for CV risk reduction.
Landmark 2023 trial showed cardiovascular benefit from semaglutide (Wegovy dose) in overweight or obese adults without type 2 diabetes — a significant expansion of known benefit beyond diabetes management.
Compared tirzepatide (5/10/15 mg) against semaglutide 1 mg in adults with type 2 diabetes. Tirzepatide arms achieved superior A1C and weight reductions at all three doses tested.
SURMOUNT-1 and SURMOUNT-2 trials established tirzepatide's efficacy for chronic weight management, supporting FDA approval of Zepbound. Average weight loss in SURMOUNT-1 reached up to 20.9% at 15 mg.
Clinical trial data consistently shows tirzepatide (Mounjaro/Zepbound) produces greater average weight loss than semaglutide (Ozempic/Wegovy). In the SURPASS-2 trial, tirzepatide outperformed semaglutide 1 mg on both A1C reduction and body weight. Individual results vary and depend on dose, adherence, duration, and patient-specific factors.
Mounjaro's dual GLP-1/GIP mechanism may offer greater average weight loss and A1C reduction than Ozempic based on head-to-head data. However, Ozempic has more established long-term cardiovascular outcome data and a longer track record in clinical practice. Neither is universally better — the right choice depends on individual health history, existing cardiovascular risk, insurance coverage, and treatment goals. Your prescriber is the right person to weigh these factors.
No. Ozempic contains semaglutide, a GLP-1 receptor agonist made by Novo Nordisk. Mounjaro contains tirzepatide, a dual GLP-1 and GIP receptor agonist made by Eli Lilly. They share a once-weekly injection schedule and a similar gastrointestinal side-effect profile, but they are distinct molecules with different mechanisms of action and different clinical trial records.
Both medications share a similar side-effect profile dominated by gastrointestinal symptoms — nausea, vomiting, diarrhea, and constipation. Both carry a black box warning for thyroid C-cell tumors and carry a risk of pancreatitis. Head-to-head tolerability comparisons across all doses are limited. Because Mounjaro is newer, its long-term safety data is still accumulating. Your prescriber can assess your individual risk profile for either medication.
Coverage varies widely by plan and by the indication on the prescription. When prescribed for type 2 diabetes, both are more likely to receive formulary coverage than when prescribed for weight loss alone. Wegovy (semaglutide) and Zepbound (tirzepatide) are the FDA-approved weight-management forms and are subject to separate, often more restrictive coverage policies. The list price for either diabetes medication is roughly $900–$1,000/month without insurance. Check your formulary directly or contact your insurer for coverage specifics.